logo
Twitter
Discord
Email
logo
Akero Therapeutics, Inc.

Akero Therapeutics, Inc.

NASDAQ•AKRO
CEO: Dr. Andrew Cheng M.D., Ph.D.
Sector: Healthcare
Industry: Biotechnology
Listing Date: 2019-06-20
Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.
Contact Information
601 Gateway Boulevard, Suite 350, South San Francisco, CA, 94080, United States
650-487-6488
akerotx.com
Market Cap
$4.50B
P/E (TTM)
-15.7
42.1
Dividend Yield
--
52W High
$58.40
52W Low
$21.34
52W Range
90%
Rank55Top 68.5%
3.0
F-Score
Modified Piotroski Analysis
Based on 8-year fundamentals
Weak • 3 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2017-2024

Financial Dashboard

Q3 2025 Data

Revenue

$0.00+0.00%
4-Quarter Trend

EPS

-$0.99-5.71%
4-Quarter Trend

FCF

-$67.17M-4.62%
4-Quarter Trend

2025 Q3 Earnings Highlights

Key Highlights

Strong Cash Position Maintained Total cash and marketable securities stood at $988.3M as of September 30, 2025, providing runway for ongoing operations.
Phase 3 Clinical Program Advances Global Phase 3 SYNCHRONY program enrollment continues for MASH treatment, building upon positive prior Phase 2b efficacy data.
R&D Investment Increased 22% Research and development expenses grew 22% to $217.7M for nine months, reflecting significant EFX advancement costs.
Definitive Merger Agreement Signed Definitive Merger Agreement signed with Novo in October 2025, offering stockholders $54.00 cash plus contingent value right.

Risk Factors

Merger Transaction Uncertainty Transaction with Novo may not close, risking material adverse effects and potential $165.0M termination fee payment.
Clinical Trial Enrollment Difficulties Clinical trial enrollment and retention for SYNCHRONY program faces difficulty due to MASH diagnosis complexity and competition.
Continued Operating Losses Accumulated deficit reached $(1.049) B as of September 30, 2025; additional funding required if merger fails to support operations.
Manufacturing Supply Chain Reliance Heavy reliance on third-party manufacturers for complex EFX API and DP production introduces supply chain and quality risks.

Outlook

SYNCHRONY Results Expected Expecting results from SYNCHRONY Real-World trial in first half of 2026 to support future marketing approval applications.
Stock Delisting Post-Merger Merger expected to close around year end; common stock will subsequently no longer be publicly listed on exchanges.
Anticipated R&D Expense Increase Anticipate substantial increase in research and development expenses supporting planned manufacturing and late-stage clinical activities.
Exploring Combination Therapies Exploring combination use of EFX with other therapies, like GLP-1 drugs, for potential greater effect in specific patient subpopulations.

Peer Comparison

Revenue (TTM)

Arrowhead Pharmaceuticals, Inc.ARWR
$596.57M
+2936.3%
Zai Lab LimitedZLAB
$441.63M
+24.1%
Soleno Therapeutics, Inc.SLNO
$98.68M
+2763.5%

Gross Margin (Latest Quarter)

Soleno Therapeutics, Inc.SLNO
98.3%
+0.0pp
uniQure N.V.QURE
89.2%
+33.9pp
NewAmsterdam Pharma Company N.V.NAMS
81.6%
-18.4pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
ARWR$9.69B-65.7-41.2%51.7%
KYMR$6.45B-26.5-33.4%7.6%
CRNX$4.79B-11.2-35.1%4.1%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
N/M
Revenue Volatile
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
0%
Cash Flow Needs Attention

Research & Insights

Next earnings:Feb 27, 2026
|
EPS:-$1.00
|
Revenue:-
Reports
All Years

  • Form 10-Q - Q3 2025

    Period End: Sep 30, 2025|Filed: Nov 7, 2025|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.99-5.7%
    N/A

  • Form 10-Q - Q2 2025

    Period End: Jun 30, 2025|Filed: Aug 8, 2025|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.86+6.2%
    N/A

  • Form 10-Q - Q1 2025

    Period End: Mar 31, 2025|Filed: May 12, 2025|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.90+0.0%
    N/A

  • Form 10-K - FY 2024

    Period End: Dec 31, 2024|Filed: Feb 28, 2025|
    Revenue: $0.00+0.0%
    |
    EPS: $-3.75-29.8%
    N/A

  • Form 10-Q - Q3 2024

    Period End: Sep 30, 2024|Filed: Nov 8, 2024|
    Revenue: $0.00+0.0%
    |
    EPS: $-1.05+47.9%
    N/A

  • Form 10-Q - Q2 2024

    Period End: Jun 30, 2024|Filed: Aug 9, 2024|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.81+35.0%
    N/A

  • Form 10-Q - Q1 2024

    Period End: Mar 31, 2024|Filed: May 10, 2024|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.90+80.0%
    N/A

  • Form 10-K - FY 2023

    Period End: Dec 31, 2023|Filed: Feb 29, 2024|
    Revenue: $0.00+0.0%
    |
    EPS: $-2.89-0.7%
    N/A